G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 27.75 SEK 3.74% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Cash & Cash Equivalents Peer Comparison

Comparables:
ALIF B
BICO
BIOT
MCAP
M
MAGLE

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Cash & Cash Equivalents
kr135.8m
CAGR 3-Years
48%
CAGR 5-Years
72%
CAGR 10-Years
41%
AddLife AB
STO:ALIF B
Cash & Cash Equivalents
kr272m
CAGR 3-Years
8%
CAGR 5-Years
35%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cash & Cash Equivalents
kr861m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Cash & Cash Equivalents
kr370m
CAGR 3-Years
1%
CAGR 5-Years
23%
CAGR 10-Years
17%
MedCap AB (publ)
STO:MCAP
Cash & Cash Equivalents
kr287.7m
CAGR 3-Years
29%
CAGR 5-Years
76%
CAGR 10-Years
15%
M
Magle Chemoswed Holding AB
STO:MAGLE
Cash & Cash Equivalents
kr7.1m
CAGR 3-Years
5%
CAGR 5-Years
26%
CAGR 10-Years
N/A

See Also

What is Genovis AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
135.8m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Cash & Cash Equivalents amounts to 135.8m SEK.

What is Genovis AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
41%

Over the last year, the Cash & Cash Equivalents growth was 19%. The average annual Cash & Cash Equivalents growth rates for Genovis AB have been 48% over the past three years , 72% over the past five years , and 41% over the past ten years .

Back to Top